Filter Results
Clinical Studies
Results filtered:Study status:
Contact Us for the Latest Status
Contact Us for the Latest Status
-
A Phase 1/2 Open-label, Multicenter Study Evaluating The Safety And Efficacy Of KITE-363 Or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, In Subjects With Relapsed And/or Refractory B-cell Lymphoma
Jacksonville, FL
Rochester, MN
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
-
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy Of KITE-753 Versus Axicabtagene Ciloleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma After First-Line Therapy
Jacksonville, FL
Rochester, MN
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy.
The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.
.